

RECEIVED

1647



JUN 27 2001

TECH CENTER 1600/2900

PATENT APPLICATION

File No.: 98-60C1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Zeren Gao, Charles E. Hart, Christopher S. Piddington, Paul O. Sheppard, Kimberly E. Shoemaker, Debra G. Gilbertson, James West

Serial No.: 09/541,752 Group Art Unit: 1647

Filed: March 31, 2000 Examiner: Spector, L.

For: GROWTH FACTOR HOMOLOG ZVEGF3

AMENDMENT FEE TRANSMITTAL

BOX NON-FEE AMENDMENT

Commissioner for Patents

Washington, DC 20231

Sir:

Transmitted herewith is an Amendment for the above-mentioned application. The fee required to be filed with the accompanying amendment has been calculated as shown below:

CLAIMS AS AMENDED

Claims Remaining After Amendment	Highest No. Covered by Previous Payments	Present Extra	Extra Rate	Fee
Total	45	- 45	0	\$9.00 \$000.00
Independent	6	- 6	0	\$40.00 \$000.00
1st Presentation of Multiple Dependent Claim			\$135.00	\$000.00
			Total	\$000.00

Applicants claim small entity status. Please charge any required fee to ZymoGenetics, Inc., Deposit Account No. 26-0290. A duplicate of this sheet is enclosed.

Respectfully submitted,

Gary E. Parker
Registration No. 31,648



RECEIVED

JUN 27 2001

TECH CENTER 1600/2900

PATENT APPLICATION

#71A18
6/27/01

I hereby certify that this correspondence is being deposited with the United States Postal Service as first-class mail in an envelope addressed to: BOX NON-FEE AMENDMENT, Commissioner for Patents, Washington, D.C. 20231.

June 18, 2001

Date



Gary E. Parker

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Gao et al.
Serial No. : 09/541,752
Filed : March 31, 2000
For : GROWTH FACTOR HOMOLOG ZVEGF3
Examiner : Spector, L.
Art Unit : 1647
Docket No. : 98-60C1
Date : June 18, 2001

BOX NON-FEE AMENDMENT
Commissioner for Patents
Washington, D.C. 20231

Response to Restriction Requirement and Amendment

Sir:

In response to the Office Action dated May 18, 2001, please amend the above-identified patent application as follows:

In the Claims:

Please replace claim 33 as follows:

A1
33. (amended) An antibody that specifically binds to an epitope of a polypeptide [according to claim 3] consisting of a sequence of amino acid residues as shown in SEQ ID NO:2 from residue 235 to residue 345.

REMARKS

Entry of the above amendment is requested. This amendment has been made for business reasons, solely to expedite the prosecution of claims drawn to certain